Compass Therapeutics, Inc. (CMPX) Form 8-K — Nov 9, 2026
Compass Therapeutics reported Q3 2026 results with a net loss of $27.2 million ($0.15/share), nearly doubling from $14.3 million a year ago, driven by a 72% jump in R&D expense to $22.0 million largely from $8.6 million in tovecimig manufacturing costs. The company is preparing a BLA submission for tovecimig in biliary tract cancer despite the FDA recommending an additional survival-benefit study first; Compass does not believe a new trial is warranted, citing COMPANION-002 data showing ORR of 18.0% vs 5.3% (p=0.0228) and median PFS of 4.7 vs 2.6 months.
Key figures
- Revenue
- 0
- Cash Position
- 163000000
- Cash runway
- into 2028
- Q3 gna expense
- 6761000
- Q3 gna yoy pct
- 126
- Q3 rnd expense
- 22039000
- Q3 rnd yoy pct
- 72
- Cash dec 31 2025
- 209000000
- Q3 2025 net loss
- 14259000
- Companion 002 orr
- 18.0% vs 5.3% (p=0.0228)
- Operating cash use
- 48000000
- Companion 002 median pfs
- 4.7 vs 2.6 months (HR=0.44, p<0.0001)
- Crossover adjusted os hr
- 0.85 (95% CI, 0.59-1.26; p=0.53)
- Nine month 2025 net loss
- 50773000
- Nine month 2026 net loss
- 70642000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.